Inhibikase Therapeutics, Inc.
IKTNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $284.55M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $1.33$2.61
- Volume (live)
- -
- Avg. volume (3M)
- 659.99K
Inhibikase Therapeutics (IKT) Stock Price & Financial Analysis
Inhibikase Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $1.58 - $1.65 |
|---|---|
| 52-Week High | $2.61 |
| 52-Week Low | $1.33 |
| Open | $1.65 |
| Volume (last close) | 310.49K |
| Average Volume (3M) | 659.99K |
| 50-Day MA | $2.21 |
|---|---|
| 200-Day MA | $1.94 |
| 1-Year Change | +6.54% |
| Market Cap | 284.55M |
|---|---|
| Shares Outstanding | 174.57M |
| Price to Book (P/B) | 1.86 |
| EV/EBITDA | -3.97 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Inhibikase Therapeutics at a Glance
As of the Oct 22, 2026 close, Inhibikase Therapeutics (IKT) has a market capitalization of $284.55M. Revenue fell 100.0% year over year.
As of its latest reported balance sheet, it holds $31.21M in cash and securities against $0.00 of debt, a net cash position of $31.21M.
Inhibikase Therapeutics does not currently pay a dividend.
The share price is up 6.5% over the past year. At $1.63 (the Oct 22, 2026 close) it sits within its 52-week range of $1.33 to $2.61, below its 200-day moving average of $1.94.
Based on 6 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $5.58, 242.3% above the Oct 22, 2026 close.
Frequently Asked Questions About Inhibikase Therapeutics
What is the current stock price for IKT?
As of the Oct 22, 2026 close, IKT stock trades at $1.63. The 52-week range is $1.33–$2.61, with a day range of $1.58–$1.65.
What is the P/E ratio for IKT?
The P/E ratio (Price-to-Earnings) for IKT is shown in the Key Statistics section. This valuation metric helps compare Inhibikase Therapeutics, Inc. to industry peers.
Does IKT pay dividends?
Inhibikase Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for IKT?
Based on ratings from 6 professional analysts over the last 90 days, the consensus for IKT is Buy. The average 12-month price target is $5.58, a 242.3% upside from the Oct 22, 2026 close of $1.63.
What is the market cap of IKT?
As of the Oct 22, 2026 close, Inhibikase Therapeutics's market capitalization is $284.6M, classifying it as a micro-cap company. Inhibikase Therapeutics operates in the Healthcare sector within the Biotechnology industry.